Unlock stock picks and a broker-level newsfeed that powers Wall Street.

The Zacks Analyst Blog Highlights ADMA, FirstCash, Stride, Life Time Group and National Fuel Gas

In This Article:

For Immediate Release

Chicago, IL – May 1, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: ADMA Biologics Inc. ADMA, FirstCash Holdings Inc. FCFS, Stride Inc. LRN, Life Time Group Holdings Inc. LTH and National Fuel Gas Co. NFG.

Here are highlights from Wednesday’s Analyst Blog:

These 5 Buy-Ranked Mid-Cap Stocks Are Flying High Year to Date

Wall Street has witnessed severe volatility in 2025 after recording an astonishing bull run in the last two years. Year to date, all three major stock indexes — the Dow, the S&P 500 and the Nasdaq Composite — are in negative territory. The small-cap benchmarks — the Russell 2000 and the S&P 600 — are also in the negative zone year to date. Similarly, the mid-cap-specific S&P 400 Index is also in the red.

Despite this headwind, a handful of mid-cap stocks are flying high providing more than 25% returns year to date. We have selected five such stocks with a favorable Zacks Rank. These are: ADMA Biologics Inc., FirstCash Holdings Inc., Stride Inc., Life Time Group Holdings Inc. and National Fuel Gas Co.

These stocks have strong revenue and earnings growth potential for 2025. Moreover, these stocks have seen positive earnings estimate revisions over the last 60 days. Each of our picks carries either a Zacks Rank #1 (Strong Buy) or 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

ADMA Biologics

ADMA Biologics is a specialty immune globulin company. ADMA develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases.

ADMA’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. ADMA sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers.

ADMA Biologics has an expected revenue and earnings growth rate of 16.3% and 44.9%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 2.9% over the last 60 days.

FirstCash Holdings

Zacks Rank #2 FirstCash Holdings operates retail pawn stores in the United States, Mexico, and rest of Latin America. FCFS operates through three segments: U.S. Pawn, Latin America Pawn, and Retail POS Payment Solutions.